K
Kiora Pharmaceuticals, Inc. (KPRX)
1.88
0.00 (0.00%)
Get all premium features to the best stock analysis tool
1.88
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.79 | 6.05 | 10 | |
| Quick ratio | 8.79 | 5.63 | 10 | |
| Debt to Equity | 0.02 | 0.30 | 9.0 | |
| Debt to Assets | 0.01 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | 16M | N/A |
| Gross Profit | -227K | -134K | -62K | 16M | -107K |
| Operating Income | -11M | -12M | -9M | 3M | -12M |
| Net Income | -14M | -14M | -13M | 4M | -9M |
| EBITDA | -10M | -12M | -9M | 3M | -12M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 44.63 | 5.5 |
| Next quarter | N/A | 13.46 | 4.5 |
| Current year | -90.64 | -296.55 | 1.0 |
| Next year | 0 | -30.41 | 1.0 |
| Weighted average score | 3.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 101.25 | 101.85 | 66.8 | 10 |
| Y/Y | 999 | 100.79 | 101.23 | -238.41 | 7.8 |
| 3y average | 999 | 45.99 | 87.63 | 66.91 | 10 |
| 5y average | 559.49 | 8.12 | 56.7 | 32.88 | 9.0 |
| Weighted average score | 9.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $5.5M significantly exceed its total debt $404.2K, ensuring strong financial flexibility
Total current assets $22.7M exceed Total current liabilities $2.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$1.3M limits the company's ability to reinvest or pay down debt